Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Lung Neoplasms 23Carcinoma, Hepatocellular 23Small Cell Lung Carcinoma 16Cholangiocarcinoma 10Breast Neoplasms 10Urinary Bladder Neoplasms 9Biliary Tract Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Liver Neoplasms 8Pancreatic Neoplasms 6Carcinoma 6Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Transitional Cell 4Ovarian Neoplasms 3Neoplasms by Site 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Bile Duct Neoplasms 3Adenocarcinoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Respiratory Tract Neoplasms 2Pathologic Complete Response 2Oropharyngeal Neoplasms 2Neoplasms by Histologic Type 2

Interventions

Magnetic Resonance Spectroscopy 12Specimen Handling 11Cisplatin 9Radiotherapy, Intensity-Modulated 7Platinum 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 5Cetuximab 5Carboplatin 5Radiation 4Biopsy 4(225)Ac-DOTA-c(RGDyK) 4Taxes 3Radiotherapy 3Paclitaxel 3ipatasertib 2cemiplimab 2X-Rays 2Interviews as Topic 2Immunoglobulin G 2Docetaxel 2Disulfides 2toripalimab 1peposertib 1merphos 1durvalumab 1dehydroftorafur 1cabozantinib 1atezolizumab 1Tretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Laryngeal Neoplasms × durvalumab × 90 days × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡